Adimab partners with Boehringer Ingelheim to discover and optimize antibodies against targets selected by BI who exclusively possesses the right to develop and commercialize therapeutic programs.
Tillman Gerngross, Chief Executive Officer and Co-Founder of Adimab said “In vivo technologies can work well for many therapeutic targets. However, with increasing demands on selectivity, develop ability; affinity, and epitopic diversity, mice are often not up to the task.”
As per the terms of the agreement, Adimab will use its proprietary yeast-based discovery and optimization platform to identify fully human antibodies against multiple targets selected by BI. For each target, Adimab will grant BI the right to evaluate antibody panels generated during the collaboration for potential use in therapeutic products.